使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings. Welcome to the Align Q4 '21 Earnings Call. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, Shirley Stacy, with Align Technology. You may begin.
各位好。歡迎參加 Align 2021 年第四季(Q4 '21)財報電話會議。(接線員指示)請注意,本次會議將被錄音。現在我將把會議交給本次主持人、Align Technology 的 Shirley Stacy。您可以開始了。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you. Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued fourth quarter and full year 2021 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com.
謝謝。各位下午好,感謝各位加入。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。我們今天已透過 GlobeNewswire 發布 2021 年第四季與全年財務結果,您可於我們網站 investor.aligntech.com 查閱。
Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. The telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on February 16. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13725950 followed by #. International callers should dial (201) 612-7415 with the same conference number.
今天的電話會議將以音訊網路直播,並將在我們網站上封存約 1 個月。電話重播將於今日美東時間約下午 5:30 起提供,並持續至 2 月 16 日美東時間下午 5:30。若要收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議編號 13725950 後按 #。國際來電者請撥打 (201) 612-7415,並輸入相同的會議編號。
As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.
提醒各位,今天提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件與產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近提交給美國證券交易委員會(SEC)的定期報告中有更詳細的說明,報告可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。
We've posted historical financial statements, including the corresponding reconciliations including our GAAP to non-GAAP reconciliation, if applicable, and our fourth quarter and full year 2021 conference call slides on our webcast -- website under quarterly results. Please refer to these files for more detailed information.
我們已在網路直播—網站的「季度結果」專區張貼歷史財務報表,包括相應的調節表(如適用,包含 GAAP 與非 GAAP 的調節),以及 2021 年第四季與全年電話會議簡報。請參閱這些檔案以取得更詳細資訊。
And with that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我將把電話會議交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights from the fourth quarter, then briefly discuss the performance of our 2 operating segments, Services Systems and Clear Aligners. John will provide more detail on our financial results and discuss our outlook. Following that, I'll come back, summarize a few key points and open the call to questions.
謝謝,Shirley。各位下午好,感謝各位加入。今天的電話會議中,我將先提供第四季的一些重點,接著簡要說明我們兩個營運部門(服務與系統,以及透明牙套)的表現。John 將更詳細說明我們的財務結果並討論展望。之後我會回來總結幾個關鍵重點,並開放提問。
Overall, I'm very pleased to report fourth quarter results and another record year -- full year for Align. Net revenues of $4 billion and operating margin of 24.7% were both at the high end of our guidance for fiscal 2021. For Systems and Services, full year revenues increased 90.4% over the prior year to a record $705.5 million. For Clear Aligners, full year revenues increased 54.5% over the prior year to a record $3.2 billion.
整體而言,我非常高興報告第四季成果,以及 Align 再創紀錄的一年—2021 全年。2021 會計年度淨營收 40 億美元與 24.7% 的營業利益率,皆位於我們指引區間的高端。就系統與服務而言,全年營收較前一年成長 90.4%,達到創紀錄的 7.055 億美元。就透明牙套而言,全年營收較前一年成長 54.5%,達到創紀錄的 32 億美元。
During 2021, we achieved several major installed base milestones, including our 12 millionth Invisalign patient, 68,000 iTero scanners sold and 47,000 exocad software license install. Together, these elements are the foundation of the Align Digital Platform, proprietary combination of software, systems and services designed to provide a seamless experience and workflow that integrates and connects all users, doctors, labs, patients and consumers.
在 2021 年,我們達成多項重要的裝機基礎里程碑,包括第 1,200 萬位 Invisalign 病患、售出 68,000 台 iTero 掃描儀,以及安裝 47,000 套 exocad 軟體授權。這些要素共同構成 Align 數位平台(Align Digital Platform)的基礎—這是一套由軟體、系統與服務組成的專有組合,旨在提供無縫體驗與工作流程,整合並連結所有使用者、醫師、技工所、病患與消費者。
For Q4, revenues reflect continued strong growth and momentum from iTero scanner services revenues, particularly in North America, offset by lower-than-expected Invisalign Clear Aligner revenues. Through most of the fourth quarter, our Clear Aligner volumes were trending in line with our Q4 seasonality. However, the environment quickly changed in December with the rise of COVID-19 Omicron variant. We believe our Q4 Clear Aligner volumes were impacted by an increase in COVID-19 Omicron cases that caused customer lab shortages from a staff standpoint, practice closures or reduced hours and less patient traffic in December, and that continued into Q1.
就第四季而言,營收反映 iTero 掃描儀服務營收持續強勁成長與動能,尤其在北美;但被低於預期的 Invisalign 透明牙套營收所抵銷。在第四季的大部分時間,我們的透明牙套量趨勢符合第四季季節性表現。然而,12 月隨著 COVID-19 Omicron 變異株的升溫,環境迅速改變。我們認為,第四季透明牙套量受到 Omicron 病例增加的影響,導致客戶端技工所人力短缺、診所關閉或縮短營業時間,以及 12 月病患來診量下降,且此情況延續至第一季。
This compounded an already slower seasonal period for many practices in which offices took time off in between the holidays. We estimate that our Q4 was negatively impacted by roughly 3 points of year-over-year revenue growth as a result of these factors.
這也加劇了許多診所在假期之間休假所造成的原本就較慢的季節性期間。我們估計,受上述因素影響,第四季年對年營收成長約被拉低了 3 個百分點。
While there are some similarities to what we experienced 2 years ago when COVID-19 first appeared, especially in China, which currently has a 0 tolerance COVID policy, the environment today is different. There aren't broad government-mandated shutdowns, stay-at-home orders or extended quarantines, but there is more consumer caution, self-imposed quarantines, higher inflation, less economic stimulus and supply chain shortages, which makes it more difficult to predict when recovery may occur. Nonetheless, Invisalign doctor submitters and case submissions are improving. We're working closely with our customers to support their needs and protect the health and safety of our employees.
雖然與兩年前 COVID-19 初次出現時的情況有一些相似之處,尤其是在目前採取 COVID 零容忍政策的中國,但今日的環境已不同。並沒有大範圍政府強制停工、居家令或延長隔離;但消費者更為謹慎、自主隔離增加、通膨較高、經濟刺激減少以及供應鏈短缺,使得更難預測何時會復甦。儘管如此,Invisalign 醫師提交者與病例提交量正在改善。我們正與客戶密切合作,以支援其需求並保障員工的健康與安全。
For Q4, Systems and Services revenues were up 61.3% year-over-year and up 21% sequentially, with strong revenue growth across all regions. Q4 results reflect the continued adoption of the iTero Element 5D Plus imaging system, which we launched last year and that features innovative technology like near-infrared technology which aids in the detection and monitoring of interproximal caries lesions or cavities above the gingiva without harmful radiation. The iTero Element 5D Plus imaging system represents 75% of iTero volumes in Q4.
第四季系統與服務營收年增 61.3%,季增 21%,各地區皆呈現強勁的營收成長。第四季結果反映 iTero Element 5D Plus 影像系統持續被採用;該系統於去年推出,具備近紅外線等創新技術,可在不使用有害輻射的情況下,協助偵測與監測牙齦上方的鄰接面齲齒病灶或蛀牙。iTero Element 5D Plus 影像系統在第四季占 iTero 出貨量的 75%。
In addition, over 50% of iTero scanner sales in Q4 were sold to first-time scanner buyers who are just beginning their Align Digital Platform journey. We also continue to see growth in our iTero scanner installed base with strong service revenues, which historically have been a leading indicator of increased digital adoption amongst doctors.
此外,第四季超過 50% 的 iTero 掃描儀銷售是賣給首次購買掃描儀的客戶,他們正開始其 Align 數位平台旅程。我們也持續看到 iTero 掃描儀裝機基礎成長,並帶動強勁的服務營收;歷史上,服務營收一直是醫師數位化採用提升的領先指標。
For Q4, Clear Aligner revenues were up 16.3% year-over-year with strong revenue growth across all regions and across the portfolio, including comprehensive and noncomprehensive products as well as Invisalign First, Invisalign Moderate and Invisalign Go products.
第四季透明牙套營收年增 16.3%,各地區及整體產品組合皆呈現強勁營收成長,包括全方位與非全方位產品,以及 Invisalign First、Invisalign Moderate 與 Invisalign Go 產品。
Our fourth quarter revenues also include non-case revenue for clinical training and education, doctor prescribed retainer products and other dental consumables. During the quarter, we saw good performance from our retainer business overall, delivering strong revenue growth, along with increased enthusiasm for the doctor subscription program pilot in North America.
我們第四季營收亦包含非病例營收,來自臨床訓練與教育、醫師處方的維持器產品以及其他牙科耗材。季度期間,我們的維持器業務整體表現良好,帶來強勁的營收成長,同時北美地區醫師訂閱方案試點也獲得更高的熱情與關注。
As we mentioned last quarter, our share of the retention market is significantly under-penetrated, even more so than our share of the orthodontic case starts. We have been developing a robust retainer strategy, including a separate marketing team focused solely on driving adoption and increasing market share in the U.S.
如同我們上季所提到的,我們在維持器市場的市占率明顯仍有很大提升空間,甚至比我們在矯正病例啟動(case starts)上的市占率更為不足。我們一直在制定更完善的維持器策略,包括成立一個獨立的行銷團隊,專注於推動採用並提升美國市場市占率。
Our objective is to build brand awareness for Vivera retainers and drive engagement with doctors through clinical education and sales initiatives while connecting consumers to doctors through demand creation programs and our concierge service. We've also recently implemented social media campaigns featuring the benefit of Vivera from the makers of Invisalign Clear Aligners. We believe that incremental investments will increase value for Invisalign practices and contribute to growth consistent with our long-term financial model target.
我們的目標是提升 Vivera 維持器的品牌知名度,並透過臨床教育與銷售推廣計畫提升與醫師的互動,同時透過需求創造計畫與我們的禮賓服務,將消費者與醫師連結起來。我們近期也推出社群媒體活動,強調由 Invisalign 透明牙套製造商推出的 Vivera 之優勢。我們相信,這些增量投資將為 Invisalign 診所帶來更高價值,並有助於達成與我們長期財務模型目標一致的成長。
Q4 non-case revenues also include accessories and consumables such as Aligner cases, clamshells, cleaning crystals, Invisalign Whitening Pen and other oral health products that are available on our e-commerce channel, including the Invisalign accessory store, Walmart.com and Amazon.com. We view these ancillary products as a natural brand extension, enabling patient and doctor behavior with the power of the Invisalign brand.
第四季非病例營收亦包含配件與耗材,例如牙套收納盒、貝殼盒、清潔晶體、Invisalign 美白筆及其他口腔健康產品;這些產品可透過我們的電商通路購買,包括 Invisalign 配件商店、Walmart.com 與 Amazon.com。我們將這些周邊產品視為自然的品牌延伸,藉由 Invisalign 品牌的力量,促進病患與醫師的使用行為。
Our full year results reflect continued adoption and demand for both the Invisalign system and iTero systems and services and exocad CAD/CAM software as more doctors transform their practices to digital and more consumers seek to transform their smiles through doctor-directed Invisalign treatment.
我們的全年結果反映 Invisalign 系統與 iTero 系統及服務,以及 exocad CAD/CAM 軟體持續被採用並具備需求;因為越來越多醫師將診所轉型為數位化,且越來越多消費者透過醫師主導的 Invisalign 治療來改變笑容。
Now let's turn to the specifics around our fourth quarter results, starting with the Americas. For the Americas region, full year 2021 Invisalign case volumes were up 57.6%. For Q4, Invisalign case volumes were up 11.5% year-over-year, reflecting growth across the region, especially in LatAm. On a sequential basis, Americas shipments were down 7.9%, primarily reflecting the impact of Omicron previously described as well as a seasonally slower teen season from Q3 to Q4. We also saw higher GP and adult case volume and continued momentum from our doctor subscription plan pilot.
現在讓我們進入第四季結果的具體細節,先從美洲地區開始。就美洲地區而言,2021 全年 Invisalign 病例量成長 57.6%。第四季 Invisalign 病例量年增 11.5%,反映整個地區的成長,尤其是拉丁美洲(LatAm)。以季比而言,美洲出貨量下降 7.9%,主要反映前述 Omicron 的影響,以及從第三季到第四季青少年旺季季節性轉弱。我們也看到一般牙科(GP)與成人病例量更高,且醫師訂閱方案試點持續帶來動能。
In Q4, we pledged a $1 million donation to the American Association of Orthodontists Foundation, the charitable arm of the American Association of Orthodontists in support of the science of orthodontics. We're also investing in education grants, programs to provide universities with greater access to all Align products for education and training purposes. Through these programs, our partnership with the Aligner Intensive Fellowship and the other in-person educational programs, we are investing in the orthodontic profession through the people who care for and treat patients directly.
在第四季,我們承諾向美國矯正牙科醫師協會基金會(American Association of Orthodontists Foundation)捐贈100萬美元;該基金會為美國矯正牙科醫師協會的慈善機構,以支持矯正牙科科學。我們也持續投資於教育補助與相關計畫,讓大學在教育與訓練用途上能更廣泛取得 Align 全系列產品。透過這些計畫、我們與 Aligner Intensive Fellowship 的合作,以及其他實體教育課程,我們正透過直接照護與治療病患的人員,投資於矯正牙科專業領域。
For Systems and Services, Q4 was a strong quarter for Americas, driven by continued adoption of iTero 5D Plus imaging system across customer channels, including our DSO partners. Services revenues continue to grow nicely, reflecting the growth of the iTero scanner installed base in North America.
在系統與服務(Systems and Services)方面,第四季對美洲地區而言是表現強勁的一季,主要受惠於 iTero 5D Plus 影像系統在各客戶通路(包括我們的 DSO 合作夥伴)持續被採用。服務營收也持續穩健成長,反映出北美 iTero 掃描儀裝機基數的擴大。
For the full year, international Invisalign case volume was up 51.6%. For our international business, Q4 Invisalign case volumes were up 10.7% year-over-year on tough comps compared to 2020. On a sequential basis, international shipments were up 1.7%. Notwithstanding the impact of Omicron in December, we still saw strong growth in EMEA, offset somewhat by a seasonally slower period primarily in China.
就全年而言,國際 Invisalign 病例量成長 51.6%。就我們的國際業務而言,在與 2020 年相比的高基期下,第四季 Invisalign 病例量年增 10.7%。以季比來看,國際出貨量成長 1.7%。儘管 12 月 Omicron 造成影響,我們在 EMEA 仍看到強勁成長,但部分被主要在中國的季節性較慢期間所抵銷。
For the full year, EMEA Invisalign volume was up 69.5%. For EMEA, Q4 Invisalign case volumes were up 14.9% year-over-year, with broad-based growth across all markets, led by Italy and Iberia, along with continued growth in our expansion markets in Turkey, Russia, CIS and Benelux. For Q4, year-over-year Invisalign case volume in EMEA was driven by increased submissions primarily from the orthodontist channel. On a sequential basis, despite the impact of Omicron, EMEA Invisalign case volume was up 13.6%, primarily as a result of strong ortho channel performance, especially in the teen market.
就全年而言,EMEA 的 Invisalign 病例量成長 69.5%。在 EMEA,第四季 Invisalign 病例量年增 14.9%,各市場普遍成長,其中以義大利與伊比利亞半島領先,並且我們在土耳其、俄羅斯、獨立國協(CIS)與比荷盧(Benelux)等擴張市場也持續成長。第四季 EMEA 的 Invisalign 病例量年增,主要由矯正醫師通路提交量增加所帶動。以季比來看,儘管 Omicron 造成影響,EMEA 的 Invisalign 病例量仍成長 13.6%,主要來自矯正通路的強勁表現,尤其是在青少年市場。
During Q4, we began commercial operation in Africa, with our initial focus on North Africa and then plan to enter Sub-Sahara Africa and South Africa this year, further broadening our expansion markets in EMEA. It's exciting opportunity for Align in this untapped and expanding totally addressable market. We're also making great progress on building our Europe and manufacturing facility in Wroclaw, Poland, which will be our third global Aligner manufacturing operation.
在第四季期間,我們開始在非洲展開商業營運,初期聚焦北非,並計畫於今年進入撒哈拉以南非洲與南非,進一步擴大我們在 EMEA 的擴張市場。對 Align 而言,這是在尚未充分開發且持續擴大的整體可服務市場(TAM)中的令人振奮機會。我們也在波蘭弗羅茨瓦夫(Wroclaw)建置歐洲製造基地方面取得重大進展,該基地將成為我們全球第三個隱形牙套(Aligner)製造營運據點。
The Europe manufacturing facility is on track to go live during the first half of 2022, further increasing our ability to efficiently provide the Invisalign system to our valued doctor customers within the European region. For Q4, we saw strong scanner shipments during the quarter as more doctors in the EMEA region continue to digitize their practices.
歐洲製造基地進度如期,預計於 2022 年上半年啟用,進一步提升我們在歐洲地區更有效率地向珍視的醫師客戶提供 Invisalign 系統的能力。第四季,我們看到掃描儀出貨強勁,因為 EMEA 地區有更多醫師持續將其診所數位化。
Through a full year APAC, Invisalign case volume was up 27.1%. For Q4, APAC Invisalign case volumes led by Japan, Korea and India were up 3.4% year-over-year on tough comps despite continued COVID resurgences and lockdown sporadically impacting various APAC countries, including China. We also saw strength in the GP dentist channel with increased Invisalign submitters and in the teen market with increased submissions from the orthodontic channel.
就全年 APAC 而言,Invisalign 病例量成長 27.1%。第四季在與高基期相比下,儘管 COVID 持續反覆與封控零星影響 APAC 多個國家(包括中國),由日本、韓國與印度帶動的 APAC Invisalign 病例量仍年增 3.4%。我們也看到一般牙醫(GP)通路表現強勁,Invisalign 提交醫師數增加;同時在青少年市場,矯正通路提交量也有所提升。
On a sequential basis, APAC was down 15.4%, notwithstanding the impact of Omicron in December and Q4 seasonality in China. We had strong growth in Thailand, Southeast Asia, Taiwan. Overall, it was encouraging to see record numbers of shipments to those markets in APAC that were not as impacted by the most severe lockdowns. In Q4, Systems and Services in APAC saw the highest percentage of iTero scanners sold to new doctors.
以季比來看,APAC 下滑 15.4%,儘管 12 月 Omicron 的影響以及中國第四季的季節性因素。我們在泰國、東南亞與台灣實現強勁成長。整體而言,令人鼓舞的是,在 APAC 中未受到最嚴格封控影響的市場,我們看到創紀錄的出貨量。第四季,APAC 的系統與服務業務中,售予新醫師的 iTero 掃描儀占比為最高。
Today, we announced new Invisalign systems innovations for the Align Digital Platform, a proprietary combination of software, systems and services designed to provide a seamless experience and workflow that integrates and connects all users, doctors, labs, patients and consumers. These new innovations include ClinCheck Live Update for 3D controls; the Invisalign Practice App; Invisalign Personalized Plan, or IPP; and the Invisalign Smile Architect.
今天,我們宣布 Align 數位平台(Align Digital Platform)的全新 Invisalign 系統創新;該平台為我們專有的軟體、系統與服務組合,旨在提供無縫體驗與工作流程,整合並連結所有使用者、醫師、技工所、病患與消費者。這些新創新包括:用於 3D 控制的 ClinCheck Live Update;Invisalign Practice App;Invisalign Personalized Plan(IPP);以及 Invisalign Smile Architect。
We believe they will revolutionize digital treatment planning for orthodontics and restorative dentistry by providing doctors with greater flexibility, consistency of treatment preferences and real-time treatment planning access and modification capabilities. Each of these innovations is designed to enhance Invisalign treatment planning quality, efficiency and scale and contribute to better doctor-patient engagement and treatment outcomes.
我們相信,這些創新將透過為醫師提供更高的彈性、更一致的治療偏好設定,以及即時的治療規劃存取與修改能力,徹底革新矯正與修復牙科的數位治療規劃。每一項創新皆旨在提升 Invisalign 治療規劃的品質、效率與規模,並促進更佳的醫病互動與治療成果。
ClinCheck Live Update for 3D controls enables real-time ClinCheck treatment plan modifications that improve practice productivity significantly while also improving quality of treatment plans. Invisalign Practice App provides mobile integration with the Invisalign Doctor Site or IDS. It enables doctors to manage their practices at their fingertips.
用於 3D 控制的 ClinCheck Live Update 可讓 ClinCheck 治療計畫進行即時修改,顯著提升診所生產力,同時改善治療計畫品質。Invisalign Practice App 提供與 Invisalign Doctor Site(IDS)的行動整合,使醫師能隨時隨地管理其診所營運。
Invisalign's Personal (sic) [Personalized] Plan, or IPP, automatically applies a doctor's specific treatment preferences for comprehensive cases, enhancing efficiency and step-changing treatment planning consistency. Invisalign Smile Architect software is designed for GP dentists to create and visualize orthodontic restorative treatment plans for their patients using iTero digital scans and wide smile photos on the Invisalign Go platform. The technical design assessment go-to-market is scheduled for Q4 '22.
Invisalign 的 Personal(原文如此)[Personalized] Plan(IPP)可針對全口病例自動套用醫師的特定治療偏好,提升效率並大幅改善治療規劃一致性。Invisalign Smile Architect 軟體則是為一般牙醫(GP)設計,讓其可在 Invisalign Go 平台上,使用 iTero 數位掃描與全笑容照片,為病患建立並視覺化矯正與修復的治療計畫。技術設計評估(technical design assessment)的上市推進(go-to-market)預計於 2022 年第四季進行。
We know that every Invisalign trained doctor has distinct preferences. Every patient is unique, and every treatment plan can vary depending on a variety of factors such as the type of malocclusion, patient age and desired outcome. Because of that, doctors spend time planning, reviewing and modifying their ClinCheck plans, and it multiplies with practice growth. IPP and ClinCheck Live Update for 3D controls are game-changing innovations that represent a step-change in digital treatment planning to help doctors achieve more personalized ClinCheck treatment plans. By using 3D controls, doctors can see greater efficiency with changes reflected in real time.
我們知道,每位受過 Invisalign 訓練的醫師都有不同偏好。每位病患都是獨特的,而每個治療計畫也會因多種因素而有所不同,例如咬合不正類型、病患年齡與期望結果。因此,醫師需要花時間規劃、審閱並修改其 ClinCheck 計畫,而這些工作量會隨著診所成長而倍增。IPP 與用於 3D 控制的 ClinCheck Live Update 是具顛覆性的創新,代表數位治療規劃的重大躍進,協助醫師達成更個人化的 ClinCheck 治療計畫。透過 3D 控制,醫師可更有效率地作出變更,且變更會即時反映。
Invisalign Smile Architect combines basically driven in ortho restorative treatment planning within the power of ClinCheck software, providing flexibility across treatment planning to address a variety of patient needs, whether it may be orthodontic, restorative or ortho restorative combined. It allows doctors to share their vision with patients and use digital technology and tools to achieve the best quality clinical outcomes for their patients.
Invisalign Smile Architect 基本上將矯正-修復整合治療規劃的驅動能力,結合於 ClinCheck 軟體的強大功能之中,提供跨治療規劃的彈性,以滿足各種病患需求,無論是矯正、修復,或矯正與修復的組合。它讓醫師能與病患分享其治療願景,並運用數位技術與工具,為病患達成最佳品質的臨床結果。
It's through the convergence of advancements in digital technology, Align's unique capabilities and know-how and data from millions of Invisalign patients that we're able to bring these new Invisalign innovations to our customers this year. The journey to deliver a ClinCheck live update in Invisalign Personal (sic) Personalized Plan has taken thousands of combined person years of development, testing and learning. It is only possible through the experience, data and insights we have gained from over 12 million Invisalign cases.
正是透過數位技術進展的匯聚、Align 獨特的能力與專業知識,以及來自數百萬名 Invisalign 病患的資料,我們才能在今年將這些全新的 Invisalign 創新帶給客戶。為在 Invisalign Personal(原文如此)Personalized Plan 中實現 ClinCheck 即時更新(live update)的歷程,已投入數千個「人年」的綜合開發、測試與學習。這只有在我們從超過 1,200 萬個 Invisalign 病例中所獲得的經驗、資料與洞見支持下才有可能。
Across our innovations, we're also using a combination of AI and automation to reimagine what the treatment planning experience looks like for our doctors, doctor customers and augmenting their expertise and experience to help them create and personalize and modify Invisalign treatment plans more efficiently and more consistently than ever before. What used to take several days can now be accomplished in just a few minutes. And it's a huge productivity win for doctors and their patients.
在各項創新中,我們也結合 AI 與自動化,重新想像醫師的治療規劃體驗樣貌,為我們的醫師客戶增強其專業與經驗,協助他們以前所未有的效率與一致性來建立、個人化並修改 Invisalign 治療計畫。過去需要數天的工作,現在只需幾分鐘即可完成。這對醫師及其病患而言,是巨大的生產力提升。
Our consumer marketing is focused on educating consumers about the Invisalign system and driving that demand to Invisalign doctors' offices, ultimately capitalizing on the massive market opportunity to transform 500 million smiles. Consumer interest in the Invisalign brand remains high, and we are continuing to invest in building the brand in key markets and customer segments. This includes investments in social media as an effective channel to increase awareness and interest for Invisalign treatment. We're continuing to work closely with our media partners to reach consumers with the right creative and compelling campaigns, optimize our buys and test new approaches.
我們的消費者行銷聚焦於教育消費者了解 Invisalign 系統,並將需求導流至 Invisalign 醫師診所,最終把握轉變 5 億個笑容的龐大市場機會。消費者對 Invisalign 品牌的興趣仍維持高檔,我們也持續在關鍵市場與客戶區隔投資品牌建設,包括投資社群媒體作為有效渠道,以提升對 Invisalign 治療的認知與興趣。我們也持續與媒體夥伴緊密合作,以適切且具吸引力的行銷活動觸及消費者,優化投放並測試新方法。
In Q4, we continued to build on our successful "Invis is" multimedia campaign across the Americas, EMEA and APAC and drove awareness and interest in Invisalign treatment with adult, teen and parent consumer segments. Globally, we delivered record impression volume with over 8 billion impressions, representing 84% year-over-year growth; and 21.7 million unique visitors to our website, a 127% increase year-over-year.
在第四季,我們持續在美洲、EMEA 與 APAC 推進成功的「Invis is」多媒體行銷活動,並在成人、青少年與家長等消費者族群中提升對 Invisalign 治療的認知與興趣。全球而言,我們創下超過 80 億次曝光的歷史新高,年增 84%;網站不重複訪客達 2,170 萬人次,年增 127%。
In the U.S., we amplified our campaigns across the top social media platforms such as TikTok, Snapchat, Instagram and YouTube to increase awareness with teens about Invisalign treatment. Our campaigns continue to feature some of the largest teen influencers from our Invisalign Smile Squad, such as Collins and Devan Key, Charli D'Amelio and Michael Le, each of whom share their personal experiences with Invisalign treatment and why they chose to transform their smiles with Invisalign aligners.
在美國,我們在 TikTok、Snapchat、Instagram 與 YouTube 等主要社群媒體平台上擴大行銷活動,以提升青少年對 Invisalign 治療的認知。我們的活動持續邀請 Invisalign Smile Squad 中一些最具影響力的青少年網紅參與,例如 Collins 與 Devan Key、Charli D'Amelio 以及 Michael Le;他們各自分享使用 Invisalign 治療的親身經驗,以及為何選擇透過 Invisalign 隱形牙套改變笑容。
Our consumer marketing programs also include connecting with teams within gaming, specifically on Twitch, with a customized integration that was awarded the gold medal in the Annual Internationalist Awards for Innovation in digital Marketing Solutions (sic) [Annual Internationalist Awards for Innovative Digital Marketing Solutions].
我們的消費者行銷計畫也包括與遊戲領域的團隊建立連結,特別是在 Twitch 上進行客製化整合,並獲得《Annual Internationalist Awards for Innovation in digital Marketing Solutions》(原文如此)[Annual Internationalist Awards for Innovative Digital Marketing Solutions] 的金獎。
To continue growing our young adult business across the Americas, EMEA and APAC, we built upon our successful "Invis is a Powerful Thing" campaign, which highlights the power of Invisalign treatment transformation for every young adult's self-confidence. Our integrated media plans across YouTube, Snapchat, Instagram, Facebook and TikTok connected with young adults in the media channels they consume the most. In Brazil, we continue to amplify our "Invis is a Powerful Thing" campaign, featuring mega influencer, Taís Araujo, driving a 400% year-over-year increase in web traffic.
為了持續在美洲、EMEA 與 APAC 擴大我們的年輕成人業務,我們在成功的「Invis is a Powerful Thing」活動基礎上再接再厲,該活動強調 Invisalign 治療轉變對每位年輕成人自信心的力量。我們在 YouTube、Snapchat、Instagram、Facebook 與 TikTok 的整合媒體計畫,於年輕成人最常使用的媒體渠道與其建立連結。在巴西,我們持續放大「Invis is a Powerful Thing」活動,邀請超級網紅 Taís Araujo 參與,帶動網站流量年增 400%。
In the EMEA region, we successfully expanded into new markets such as Italy and the Netherlands. To complement our integrated media plan with Google and YouTube, we also leveraged newer media channels such as TikTok and Snapchat to drive engagement with consumers, resulting in more than 170% year-over-year increase in unique visitors. We continue to expand our investment in consumer advertising across the APAC region, resulting in a 192% year-over-year increase in unique visitors and a 235% year-over-year increase in impressions.
在 EMEA 地區,我們成功拓展至義大利與荷蘭等新市場。為了補強我們與 Google 與 YouTube 的整合媒體計畫,我們也運用 TikTok 與 Snapchat 等較新的媒體渠道來提升消費者互動,使不重複訪客數年增超過 170%。我們也持續擴大在 APAC 地區的消費者廣告投資,使不重複訪客數年增 192%,曝光次數年增 235%。
We continue to strengthen our investments in Australia, leveraging leading influencers featured in premium placements in TikTok and also YouTube. In Japan, we continue to see strong response from consumers, as evidenced by 117% year-over-year increase in unique visitors. Lastly, we expanded our advertising investments in India and Taiwan, which generated a strong consumer response. We saw 1,200% and 628% increase in impressions and a 470% and 116% increase in unique visitors to our website in India and Taiwan, respectively.
我們持續強化在澳洲的投資,運用頂尖網紅,並在 TikTok 及 YouTube 的優質版位投放。在日本,我們持續看到消費者的強勁回應,不重複訪客數年增 117% 即為明證。最後,我們擴大在印度與台灣的廣告投資,帶來強勁的消費者回應。印度與台灣的曝光次數分別增加 1,200% 與 628%,而造訪我們網站的不重複訪客數分別增加 470% 與 116%。
Adoption of our consumer and patient app, My Invisalign, continues to increase with 1.4 million downloads to date. Usage of our 4 digital tools continues to increase. For example, in addition to My Invisalign just mentioned, the Invisalign Virtual Appointment tool was used over 14,000 times, and our insurance verification feature was used 24,000 times in Q4. Further, globally, we received more than 45,000 patient photos in our Virtual Care feature globally, which continues to provide us with rich data to leverage our AI capabilities and improve our services for doctors and patients.
我們的消費者與患者 App「My Invisalign」的採用率持續提升,迄今下載量達 140 萬次。我們的 4 項數位工具使用量也持續增加。例如,除了剛提到的 My Invisalign 之外,Invisalign Virtual Appointment 工具使用次數超過 14,000 次,而保險驗證功能在第四季使用了 24,000 次。此外,在全球範圍內,我們在 Virtual Care 功能中收到超過 45,000 張患者照片;這些資料持續為我們提供豐富數據,以運用 AI 能力並改善我們對醫師與患者的服務。
Our Systems and Services business, Q4 revenues grew 61.3% year-over-year, reflecting strong scanner shipments and services up 21% sequentially. This is the sixth consecutive quarter of sequential revenue growth for our Systems and Services business. And I as mentioned earlier, over 50% of scanner sales in Q4 went to first-time iTero scanner buyers. We're pleased to see doctors continue to go digital and invest in the Align Digital Platform.
我們的系統與服務(Systems and Services)業務方面,第四季營收年增 61.3%,反映掃描器出貨強勁,且服務營收較前一季成長 21%。這是我們系統與服務業務連續第六季的逐季營收成長。並且如我先前提到,第四季超過 50% 的掃描器銷售來自首次購買 iTero 掃描器的客戶。我們很高興看到醫師持續數位化並投資於 Align 數位平台(Align Digital Platform)。
The iTero Element 5D Plus imaging system continued to gain traction across all regions, with the most recent launch in China during Q4. The series expands the portfolio of iTero Element scanners and imaging systems to include new solutions that more broadly serve the needs of doctors and patients in the dental market.
iTero Element 5D Plus 影像系統在各地區持續獲得採用,並於第四季在中國完成最新上市。該系列擴充了 iTero Element 掃描器與影像系統的產品組合,納入可更廣泛滿足牙科市場中醫師與患者需求的新解決方案。
A strong indicator of digital acceleration within the dental offices is the number of intraoral digital scans used for Invisalign case submissions. Total worldwide intraoral digital scans submitted to start an Invisalign case in Q4 increased to 85.4% from 79.3% in Q4 last year. International intraoral digital scans for Invisalign case submissions increased 80.8%, up from 73.7% in the same quarter last year. For the Americas, 89.1% of the Invisalign cases were submitted using an intraoral digital scan compared to 84% in the same quarter last year. Cumulatively, over 50 million orthodontic scans and 10.3 million restorative scans have been performed with iTero scanners.
衡量牙科診所數位加速的一項強力指標,是用於提交 Invisalign 病例的口內數位掃描數量。第四季全球用於啟動 Invisalign 病例的口內數位掃描提交占比提升至 85.4%,高於去年同期第四季的 79.3%。國際市場用於 Invisalign 病例提交的口內數位掃描占比提升至 80.8%,高於去年同季的 73.7%。在美洲地區,第四季有 89.1% 的 Invisalign 病例以口內數位掃描提交,相較去年同季為 84%。累計而言,使用 iTero 掃描器已完成超過 5,000 萬次矯正掃描與 1,030 萬次修復掃描。
With the continued growth of the iTero scanner at 68,000 scanners sold worldwide as of Q4, approximately 30% is services revenue, which includes reoccurring revenue subscriptions, CAD/CAM software and ancillary products. And we continue to make improvements in our scanner and imaging systems, making iTero systems and service an integral part of orthodontic and GP dentist workflow. For example, we streamlined the Invisalign case submission process with the iTero Element 5D imaging systems auto-upload functionality.
隨著 iTero 掃描器持續成長,截至第四季全球已售出 68,000 台掃描器,其中約 30% 為服務營收,包括經常性訂閱收入、CAD/CAM 軟體與周邊產品。我們也持續改良掃描器與影像系統,使 iTero 系統與服務成為矯正科與一般牙科(GP)醫師工作流程中不可或缺的一部分。例如,我們透過 iTero Element 5D 影像系統的自動上傳功能,簡化了 Invisalign 病例提交流程。
Turning to exocad. For Q4 Systems and Services, revenues also include exocad CAD/CAM products and services. exocad's expertise in restorative dentistry, implantology, guided surgery and smile design extends our digital dental solutions and broadens Align Digital Platform towards a fully integrated interdisciplinary end-to-end workflows.
接著談 exocad。第四季系統與服務營收亦包含 exocad 的 CAD/CAM 產品與服務。exocad 在修復牙科、植牙學、導引手術與微笑設計方面的專業,延伸了我們的數位牙科解決方案,並推動 Align 數位平台朝向完全整合、跨專科、端到端的工作流程發展。
Cumulatively, as of Q4, exocad now has over 47,000 software license worldwide. During the quarter, exocad announced the release of ChairsideCAD 3.0 Galway. It's a next generation of easy-to-use CAD software for single-visit dentistry. With this new release, exocad offers dentists design tools for a vast range of indications with a wide choice of integrated devices.
累計截至第四季,exocad 目前在全球已擁有超過 47,000 份軟體授權。於本季,exocad 宣布推出 ChairsideCAD 3.0 Galway。這是一款新一代、易於使用的 CAD 軟體,適用於單次就診(single-visit)牙科治療。透過此次新版本,exocad 為牙醫提供可涵蓋廣泛適應症的設計工具,並可選擇多種整合式設備。
Also during the quarter, exocad announced the availability of ChairsideCAD 3.0 Galway software in the U.S. and Canada, where the software is now available in North America, EU and other selected markets. exocad's ChairsideCAD is groundbreaking open architecture CAD software for single-visit dentistry. It received the 2021 Cellerant Best of Class Technology Award from Cellerant Consulting Group during the quarter as well. This is the third consecutive year that ChairsideCAD has been recognized for this award.
同樣在本季,exocad 宣布 ChairsideCAD 3.0 Galway 軟體已可在美國與加拿大取得,使該軟體目前已在北美、歐盟及其他特定市場供應。exocad 的 ChairsideCAD 是一款具突破性的開放式架構 CAD 軟體,適用於單次就診牙科治療。本季該軟體亦獲 Cellerant Consulting Group 頒發 2021 年 Cellerant Best of Class Technology Award。這是 ChairsideCAD 連續第三年獲得此獎項肯定。
With that, I'll now turn this over to John.
接下來,我把時間交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q4 financial results. Total revenues for the fourth quarter were $1.031 billion, up 1.5% from the prior quarter and up 23.6% from the corresponding quarter a year ago. For Clear Aligners, Q4 revenues of $815.3 million were down 2.7% sequentially due to lower Invisalign volumes, partially offset by slightly higher ASPs; and up 16.3% year-over-year, reflecting Invisalign volume growth across all geographies and higher ASPs.
謝謝,Joe。接著說明我們第四季的財務結果。第四季總營收為 10.31 億美元,較前一季成長 1.5%,較去年同期成長 23.6%。在透明牙套(Clear Aligners)方面,第四季營收為 8.153 億美元,因 Invisalign 出貨量較低而較前一季下滑 2.7%,但部分被平均銷售單價(ASP)略為提高所抵銷;較去年同期成長 16.3%,反映各地區 Invisalign 出貨量成長及 ASP 提高。
In Q4, we shipped 631,100 Invisalign cases, a decrease of 3.7% sequentially, an increase of 11.1% year-over-year. In addition, we shipped to 83,500 Invisalign doctors worldwide, of which over 6,400 were to first-time customers.
第四季我們出貨 631,100 件 Invisalign 病例,較前一季減少 3.7%,較去年同期增加 11.1%。此外,我們向全球 83,500 位 Invisalign 醫師出貨,其中超過 6,400 位為首次合作客戶。
Q4 comprehensive volume increased 13.1% year-over-year and decreased 4.5% sequentially. And Q4 noncomprehensive volume increased 6.6% year-over-year and decreased 1.7% sequentially. Q4 adult patients increased 10.4% year-over-year and increased 0.1% sequentially. In Q4, teens or younger patients increased 13% year-over-year and decreased 11.8% sequentially.
第四季綜合型(comprehensive)出貨量年增 13.1%,較前一季下降 4.5%。第四季非綜合型(noncomprehensive)出貨量年增 6.6%,較前一季下降 1.7%。第四季成人患者年增 10.4%,較前一季增加 0.1%。第四季青少年或更年幼患者年增 13%,較前一季下降 11.8%。
Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $11.4 million or approximately 1.4 points sequentially. On a year-over-year basis, Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $1.5 million or approximately 0.2 points.
透明牙套營收受到外匯影響而不利,約為 1,140 萬美元,或逐季約 1.4 個百分點。以年對年基礎而言,透明牙套營收受到外匯影響而不利,約為 150 萬美元,或約 0.2 個百分點。
For Q4, Invisalign comprehensive ASPs increased sequentially and year-over-year. On a sequential basis, Invisalign comprehensive ASPs reflect higher additional liners, partially offset by unfavorable foreign exchange and higher discounts. On a year-over-year basis, comprehensive ASPs reflect higher additional aligners, partially offset by higher discounts.
在第四季,Invisalign 全方案(comprehensive)ASP 以季增及年增方式上升。就季比而言,Invisalign 全方案 ASP 反映額外襯墊(liners)增加,但部分被不利的外匯影響及較高折扣所抵銷。就年比而言,全方案 ASP 反映額外隱形牙套(aligners)增加,但部分被較高折扣所抵銷。
Q4 Invisalign noncomprehensive ASPs decreased sequentially and increased year-over-year. On a sequential basis, Invisalign noncomprehensive ASPs were unfavorably impacted by foreign exchange, partially offset by higher additional aligners. On a year-over-year basis, Invisalign noncomprehensive ASPs reflect higher additional aligners and product mix, partially offset by higher discounts.
第四季 Invisalign 非全方案(noncomprehensive)ASP 季減、年增。就季比而言,Invisalign 非全方案 ASP 受到外匯不利影響,但部分被額外隱形牙套增加所抵銷。就年比而言,Invisalign 非全方案 ASP 反映額外隱形牙套增加及產品組合影響,但部分被較高折扣所抵銷。
Clear Aligner deferred revenues on the balance sheet increased $68.5 million or 6.9% sequentially and $332.9 million or 45.8% year-over-year and will be recognized as the additional aligners are shipped.
資產負債表上的透明矯正器(Clear Aligner)遞延收入季增 6.9%(增加 6,850 萬美元),年增 45.8%(增加 3.329 億美元),並將在額外隱形牙套出貨時認列。
Our Systems and Services revenues for the fourth quarter were a record $215.8 million, up 21% sequentially and up 61.3% year-over-year. This marks the sixth consecutive quarter of sequential revenue growth. The increase sequentially can be attributed to increased scanner shipments and increased service revenues from our larger installed base.
我們第四季系統與服務(Systems and Services)營收創下 2.158 億美元新高,季增 21%,年增 61.3%。這是連續第六季營收季增。季比增加可歸因於掃描儀出貨量增加,以及因裝機基數擴大而帶動的服務營收增加。
The increase year-over-year can be attributed to increased scanner shipments, increased service revenues from our larger installed base as well as higher ASPs from the favorable mix shift towards higher-priced iTero 5D scanners and imaging systems.
年比增加可歸因於掃描儀出貨量增加、因裝機基數擴大而帶動的服務營收增加,以及因產品組合有利轉向較高單價的 iTero 5D 掃描儀與影像系統而帶來較高 ASP。
Our Systems and Services deferred revenue on the balance sheet was up $42.6 million or 22.8% sequentially and up $116.2 million or 102.6% year-over-year, primarily due to the increase in scanner sales and the deferral of services revenues, which will be recognized ratably over the service period.
資產負債表上的系統與服務遞延收入季增 22.8%(增加 4,260 萬美元),年增 102.6%(增加 1.162 億美元),主要由於掃描儀銷售增加以及服務營收遞延;該等遞延服務營收將於服務期間按比例認列。
Moving on to gross margin. Fourth quarter overall gross margin was 72.2%, down 2.1 points sequentially and down 0.9 points year-over-year. On a non-GAAP basis, excluding stock-based compensation expense and amortization of intangibles related to acquisitions, overall gross margin was 72.6% for the fourth quarter, down 2.1 points sequentially and down 0.9 points year-over-year. Overall gross margin was unfavorably impacted by approximately 0.1 points on a year-over-year basis and by approximately 0.4 points sequentially due to foreign exchange.
接著談毛利率。第四季整體毛利率為 72.2%,季減 2.1 個百分點,年減 0.9 個百分點。以非 GAAP 基礎(排除股票基礎薪酬費用及與併購相關之無形資產攤銷)計算,第四季整體毛利率為 72.6%,季減 2.1 個百分點,年減 0.9 個百分點。整體毛利率在年比方面約受外匯不利影響 0.1 個百分點,在季比方面約受外匯不利影響 0.4 個百分點。
Clear Aligner gross margin for the fourth quarter was 74.2%, down 2 points sequentially due to higher freight costs and additional aligners, along with lower primary shipments, partially offset by higher ASPs. Clear Aligner gross margin was down 0.6 points year-over-year due to higher additional aligners and higher freight costs, partially offset by higher ASPs and improved manufacturing absorption due to higher volumes.
第四季透明矯正器(Clear Aligner)毛利率為 74.2%,季減 2 個百分點,主要因運費成本上升與額外隱形牙套增加,以及主要出貨量下降;部分被較高 ASP 所抵銷。透明矯正器毛利率年減 0.6 個百分點,主要因額外隱形牙套增加與運費成本上升;部分被較高 ASP 及因出貨量提高而帶來的製造吸收改善所抵銷。
Systems and Services gross margin for the fourth quarter was 64.7%, down 0.9 points sequentially, primarily due to higher freight costs and increased component costs, partially offset by higher ASP from 5D Plus mix and higher service revenues. Systems and Services gross margin was up 0.4 points year-over-year due to higher ASP from higher mix of iTero 5D Plus and higher service revenues, partially offset by higher freight costs and increased component costs.
第四季系統與服務毛利率為 64.7%,季減 0.9 個百分點,主要因運費成本上升與零組件成本增加;部分被 5D Plus 組合占比提升帶來的較高 ASP 以及較高服務營收所抵銷。系統與服務毛利率年增 0.4 個百分點,主要因 iTero 5D Plus 組合占比提高帶來較高 ASP 及較高服務營收;部分被運費成本上升與零組件成本增加所抵銷。
We are actively engaged in activities to mitigate supply disruptions by expanding supplier communications, modifying our purchase order coverage and increasing inventory levels for key components.
我們正積極投入各項措施以緩解供應中斷,包括加強與供應商溝通、調整採購訂單涵蓋範圍,以及提高關鍵零組件的庫存水位。
Q4 operating expenses were $523.7 million, up sequentially 6% and up 31.8% year-over-year. On a sequential basis, operating expenses were up by $29.7 million. Year-over-year operating expenses increased by $126.4 million, reflecting increased headcount and our continued investment in marketing, sales, in R&D activities and other investments commensurate with business growth.
第四季營業費用為 5.237 億美元,季增 6%,年增 31.8%。就季比而言,營業費用增加 2,970 萬美元。就年比而言,營業費用增加 1.264 億美元,反映人力增加,以及我們持續在行銷、銷售、研發活動及其他與業務成長相匹配的投資。
On a non-GAAP basis, excluding stock-based compensation and amortization of acquired intangibles related to certain acquisitions, operating expenses were $494.4 million, up sequentially 6.1% and up 32.8% year-over-year due to the reasons described earlier.
以非 GAAP 基礎(排除股票基礎薪酬及與部分併購相關之取得無形資產攤銷)計算,營業費用為 4.944 億美元,季增 6.1%,年增 32.8%,原因如前所述。
Our fourth quarter operating income of $220.9 million resulted in an operating margin of 21.4%, down 4.3 points sequentially and down 4.1 points year-over-year. The sequential and year-over-year decreases in operating margin are primarily attributed to lower gross margin, investments in our go-to-market teams and technology as well as unfavorable impact from foreign exchange.
第四季營業利益為 2.209 億美元,營業利益率為 21.4%,季減 4.3 個百分點,年減 4.1 個百分點。營業利益率的季比與年比下降主要歸因於毛利率較低、對我們的市場推進(go-to-market)團隊與技術的投資,以及外匯的不利影響。
On a non-GAAP basis, which excludes stock-based compensation and amortization of intangibles related to certain acquisitions, operating margin for the fourth quarter was 24.7%, down 4.1 points sequentially and down 4.3 points year-over-year.
以非 GAAP 基礎(排除股票基礎薪酬及與部分併購相關之無形資產攤銷)計算,第四季營業利益率為 24.7%,季減 4.1 個百分點,年減 4.3 個百分點。
Interest and other income and expense net for the fourth quarter was a loss of $0.9 million, down sequentially by $1.7 million and down year-over-year by $2.2 million. The GAAP tax rate for the fourth quarter was 13.2% compared to 30.9% in the third quarter and 25.9% in the fourth quarter of the prior year.
第四季利息及其他損益淨額為虧損 90 萬美元,季減 170 萬美元,年減 220 萬美元。第四季 GAAP 稅率為 13.2%,相較第三季為 30.9%,以及去年第四季為 25.9%。
Our non-GAAP effective tax rate was 11.5% in the fourth quarter compared to 22.2% in the third quarter and 14.5% in the fourth quarter of the prior fourth quarter. The fourth quarter GAAP and non-GAAP effective tax rates reflected an out-of-period adjustment, which reduced our tax rates by 7.3% and 6.3%, respectively.
我們第四季非 GAAP 有效稅率為 11.5%,相較第三季為 22.2%,以及去年第四季為 14.5%。第四季 GAAP 與非 GAAP 有效稅率反映一項跨期調整(out-of-period adjustment),分別使我們的稅率降低 7.3% 與 6.3%。
Fourth quarter net income per diluted share was $2.40, up sequentially $0.12 and up $0.40 compared to the prior year. On a non-GAAP basis, net income per diluted share was $2.83 for the fourth quarter, down $0.04 sequentially and up $0.22 year-over-year. For the full year, net income per diluted share was $9.69, down $12.72 year-over-year due to the onetime tax benefit in 2020 of approximately $1.5 billion associated with our corporate structure reorganization completed during the first quarter of 2020. On a non-GAAP basis, net income per diluted share was $11.22 for the full year, up $5.97 year-over-year.
第四季稀釋後每股淨利為 2.40 美元,季增 0.12 美元,較去年同期增加 0.40 美元。以非 GAAP 基礎計算,第四季稀釋後每股淨利為 2.83 美元,季減 0.04 美元,年增 0.22 美元。全年稀釋後每股淨利為 9.69 美元,年減 12.72 美元,係因 2020 年一次性稅務利益所致;該稅務利益約 15 億美元,與我們於 2020 年第一季完成的公司架構重組相關。以非 GAAP 基礎計算,全年稀釋後每股淨利為 11.22 美元,年增 5.97 美元。
Moving on to the balance sheet. As of December 31, 2021, cash, cash equivalents and short-term and long-term marketable securities were $1.3 billion, up sequentially $58.8 million and up $335.8 million year-over-year. Of our $1.3 billion balance, $582.9 million was held in the U.S. and $713.8 million was held by our international entities.
接著談資產負債表。截至 2021 年 12 月 31 日,現金、約當現金以及短期與長期有價證券為 13 億美元,季增 5,880 萬美元,年增 3.358 億美元。在 13 億美元餘額中,5.829 億美元持有於美國,7.138 億美元由我們的國際實體持有。
Q4 accounts receivable balance was $897.2 million, up approximately 4.9% sequentially. Our overall days sales outstanding was 78 days, up approximately 3 days sequentially and up approximately 7 days as compared to Q4 last year. Cash flow from operations for the fourth quarter was $272.8 million. Capital expenditures for the fourth quarter were $109.1 million, primarily related to our continued investment in increasing aligner manufacturing capacity and facilities.
第四季應收帳款餘額為 8.972 億美元,季增約 4.9%。整體應收帳款週轉天數(DSO)為 78 天,季增約 3 天,較去年第四季增加約 7 天。第四季營運活動現金流量為 2.728 億美元。第四季資本支出為 1.091 億美元,主要與我們持續投資以提升隱形牙套製造產能與設施相關。
Free cash flow, defined as cash flow from operations less capital expenditures, amounted to $163.8 million. In November 2021, we purchased $100 million of our common stock through an accelerated share repurchase, which was approximately 0.2 million shares at an average price of $666.53 per share. We have approximately $725 million remaining available for repurchase under our May 13, 2021, $1 billion repurchase program.
自由現金流量(定義為營運活動現金流量減資本支出)為 1.638 億美元。2021 年 11 月,我們透過加速股份回購(accelerated share repurchase)買回 1 億美元普通股,約 20 萬股,平均每股價格為 666.53 美元。依據我們於 2021 年 5 月 13 日啟動的 10 億美元回購計畫,目前尚有約 7.25 億美元可供回購。
Before I move to our outlook, I would like to make a few comments on our full year 2021 results. In 2021, we shipped a record 2.5 million Invisalign cases, up 54.8% year-over-year. This reflects 51.6% volume growth from our international doctors and 57.6% volume growth from our Americas doctors.
在我談到展望之前,我想就我們 2021 年全年業績做幾點說明。2021 年,我們出貨 Invisalign 病例(cases)創紀錄達 250 萬件,年增 54.8%。其中反映國際醫師端出貨量成長 51.6%,以及美洲地區醫師端出貨量成長 57.6%。
Total revenues were a record $4 billion, up 59.9% year-over-year, with Clear Aligner revenues a record $3.2 billion, up 54.5% year-over-year. 2021 Systems and Services revenue were a record $705.5 million compared to $370.5 million in 2020, up 90.4% year-over-year. Full year 2021 GAAP operating income of $976.4 million was up 152.2% versus 2020, and operating margin at 24.7% versus 15.7% in 2020. On a non-GAAP basis, 2021 operating margin was 27.9% versus 20.3% in 2020.
總營收創下40億美元新高,年增59.9%;其中透明矯正器(Clear Aligner)營收創下32億美元新高,年增54.5%。2021年系統與服務(Systems and Services)營收創下7.055億美元新高,較2020年的3.705億美元增加,年增90.4%。2021年全年GAAP營業利益為9.764億美元,較2020年成長152.2%;營業利益率為24.7%,高於2020年的15.7%。以非GAAP基礎計,2021年營業利益率為27.9%,高於2020年的20.3%。
2021 interest income and other income and expense net of $36 million included the SmileDirectClub arbitration award gain of $43.4 million. Excluding the SmileDirectClub arbitration award gain, interest and other income and expense was $7.4 million expense on a non-GAAP basis.
2021年利息收入及其他收入與費用淨額為3,600萬美元,其中包含SmileDirectClub仲裁裁決收益4,340萬美元。若排除SmileDirectClub仲裁裁決收益,則以非GAAP基礎計,利息及其他收入與費用為740萬美元費用。
With regards to full year tax provision, our GAAP tax rate was 23.7%. The full year tax rate on a non-GAAP basis was 18.5% compared to 17.6% for 2020. 2021 diluted EPS was $9.69. On a non-GAAP basis, 2021 diluted EPS was $11.22. Free cash flow was $771.4 million for 2021, up $264.2 million versus 2020.
就全年所得稅費用而言,我們的GAAP有效稅率為23.7%。以非GAAP基礎計,全年有效稅率為18.5%,相較2020年的17.6%。2021年稀釋每股盈餘(EPS)為9.69美元;以非GAAP基礎計,2021年稀釋EPS為11.22美元。2021年自由現金流為7.714億美元,較2020年增加2.642億美元。
Overall, we are pleased with our Q4 results and another record year for Align. We delivered strong growth and profitability, in line with our guidance despite disruptions late in the quarter from Omicron and other factors. Our Q4 revenue year-over-year growth was within our long-term model despite disruptions impacting roughly 3 points of growth.
整體而言,我們對第四季(Q4)業績以及Align再度創下紀錄的一年感到滿意。儘管季度末受到Omicron及其他因素干擾,我們仍依照指引交出強勁的成長與獲利表現。我們第四季營收年增率仍落在長期模型範圍內,儘管干擾因素約影響了約3個百分點的成長。
We continue to see strong momentum and demand for our Systems and Services throughout Q4, with the majority of scanners being sold to first-time buyers. We believe this is a good leading indicator of future Invisalign growth as our customers continue to invest in digital technology even during COVID.
我們在第四季持續看到系統與服務(Systems and Services)強勁的動能與需求,多數掃描儀銷售給首次購買者。我們認為這是未來Invisalign成長的良好領先指標,因為即使在COVID期間,我們的客戶仍持續投資數位技術。
Let me turn to our outlook. We would normally expect sequentially higher Invisalign revenues and lower Systems and Services revenue, consistent with the typical Q1 seasonality. However, due to the continued impact of Omicron into Q1, we now expect our total Q1 revenue to be slightly down sequentially.
接下來談展望。依照第一季(Q1)典型的季節性,我們通常預期Invisalign營收將較前一季增加,而系統與服務營收將較前一季下降。然而,由於Omicron影響延續至第一季,我們目前預期第一季總營收將較前一季略為下滑。
We remain confident in our strategy, our huge under-penetrated market opportunity, our industry leadership and our ability to execute. These factors have guided our approach throughout the pandemic, where we continued to invest in new technology, commercial expansion and manufacturing capabilities to drive our growth.
我們對自身策略、龐大且滲透率仍低的市場機會、產業領導地位以及執行能力仍充滿信心。這些因素在整個疫情期間引導我們的作法:我們持續投資新技術、商業擴張與製造能力,以推動成長。
We plan to continue these investments in Q1 and therefore expect our Q1 operating margin to be less than 20%. In addition, during Q1 2022, we expect to repurchase up to $75 million of our common stock through either a combination of open market repurchases or an accelerated stock repurchase agreement.
我們計畫在第一季持續進行上述投資,因此預期第一季營業利益率將低於20%。此外,在2022年第一季期間,我們預期將透過公開市場回購或加速股票回購協議(accelerated stock repurchase agreement),或兩者的組合,回購最多7,500萬美元的普通股。
Turning to full year 2022. Despite Omicron headwinds, we expect 2022 revenue growth to be in line with our long-term model range of 20% to 30%. Our 2022 guidance assumes no significant new COVID surges after the current wave, no meaningful practice disruptions, no material supply chain issues throughout the year.
再來看2022年全年。儘管面臨Omicron逆風,我們預期2022年營收成長將符合我們長期模型的20%至30%區間。我們的2022年指引假設在目前這波疫情之後不會出現重大的新增COVID激增、不會有顯著的診所營運中斷,且全年不會出現重大的供應鏈問題。
On a GAAP basis, we anticipate our 2022 operating margin to be around 24%. On a non-GAAP basis, we expect 2022 operating margin to be approximately 3 points higher than our GAAP operating margin after excluding stock-based compensation and intangible amortization from certain acquisitions.
以GAAP基礎計,我們預期2022年營業利益率約為24%。以非GAAP基礎計,在排除股票基礎報酬以及特定收購案的無形資產攤銷後,我們預期2022年營業利益率將較GAAP營業利益率高約3個百分點。
For 2022, we expect our investments in capital expenditures to exceed $350 million. Capital expenditures primarily relate to building construction and improvements as well as additional manufacturing capacity to support our international expansion. This includes our planned investment in a Clear Aligner manufacturing facility in Wroclaw, Poland, which is expected to begin serving doctors in 2022 as part of our strategy to bring operational facilities closer to customers.
2022年,我們預期資本支出投資將超過3.5億美元。資本支出主要與建築工程與改善,以及為支持國際擴張而增加的製造產能相關。其中包括我們計畫投資於波蘭弗羅茨瓦夫(Wroclaw)的透明矯正器(Clear Aligner)製造設施;該設施預期將於2022年開始為醫師提供服務,作為我們將營運設施更貼近客戶之策略的一部分。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來我把時間交回Joe做最後的評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John. Overall, despite the disruption from the Omicron in December, we delivered a record year with strong revenue growth and operating margin, in line with our guidance for the full year on top of a record Q4 and 2020 a year ago.
謝謝,John。整體而言,儘管12月受到Omicron干擾,我們仍交出創紀錄的一年,營收成長與營業利益率強勁,符合我們對全年指引;而且是在去年同樣創紀錄的第四季與2020年高基期之上達成。
As we look back, I wanted to take a moment to recognize our accomplishments and thank our employees and our customers for another remarkable year. In the face of ongoing challenges related to COVID-19 and economic uncertainty, we remain steadfast in our commitment to our employees, customers and the focused execution of our strategic initiatives. And our customers remain confident in our ability to support them.
回顧過去,我想花點時間肯定我們的成就,並感謝員工與客戶再度成就非凡的一年。面對與COVID-19及經濟不確定性相關的持續挑戰,我們仍堅定承諾支持員工與客戶,並專注執行我們的策略性計畫。我們的客戶也持續對我們支援他們的能力充滿信心。
Operating in this environment has not been easy, but after 2 years of navigating uncharted waters, the Align team is more agile and resilient than ever. In 2021, we met our goals and achieved numerous milestones. Globally, we delivered across each of our strategic priorities, which are highlighted in our Q4 '21 webcast slides. Our performance over the last year reaffirms the incredible size of our target market and demonstrates that our strategy and investment in recent years are validated by the trust and faith our customers place in us.
在這樣的環境下營運並不容易,但在兩年來航行於未知水域之後,Align團隊比以往更敏捷、更具韌性。2021年,我們達成目標並取得多項里程碑。在全球範圍內,我們在各項策略優先事項上皆有交付成果,這些重點已在我們2021年第四季(Q4 '21)網路直播簡報中呈現。過去一年的表現再次印證我們目標市場的驚人規模,也顯示我們近年來的策略與投資,已獲得客戶對我們的信任與信心所驗證。
In 2022, we must continue to extend our leadership in digital orthodontics and restorative dentistry through relentless execution of our strategic initiatives, focusing on expanding our commercial, manufacturing, R&D, clinical, treatment planning and manufacturing operations and building our quality and regulatory muscle globally in existing and emerging markets, reaching millions of consumers who want to transform their smiles using the most advanced Clear Aligner systems in the world through the right investments in advertising, PR, digital, social media and influencer marketing to drive demand and conversion through Invisalign trained doctors.
2022年,我們必須透過不懈地執行策略性計畫,持續擴大我們在數位齒顎矯正與修復牙科領域的領導地位,聚焦於擴展我們的商業、製造、研發、臨床、治療規劃與製造營運,並在既有與新興市場中於全球強化品質與法規能力;同時,透過在廣告、公關、數位、社群媒體與網紅行銷上的適當投資,觸及數以百萬計希望使用全球最先進透明矯正器(Clear Aligner)系統來改變笑容的消費者,並透過受過Invisalign訓練的醫師推動需求與轉換。
Invisalign ortho adoption and teen utilization of Invisalign treatment and training and educating GP dentists on how the iTero Element family of intraoral scanners and imaging systems can propel today's dental practice into the future by enhancing patient experience and elevating clinical precision and on the benefits of digital dentistry with the Invisalign system trusted by more than 12 million people worldwide to transform smiles.
推動Invisalign在矯正領域的採用,以及青少年使用Invisalign治療的比重,並對一般牙科醫師(GP)進行訓練與教育,讓他們了解iTero Element系列口內掃描儀與影像系統如何透過提升病患體驗與臨床精準度,推動當今牙科診所邁向未來;同時也讓他們了解數位牙科的效益,以及這套獲全球超過1,200萬人信賴、用以改變笑容的Invisalign系統。
We remain mindful of the ongoing uncertainty surrounding COVID-19 and the challenges that go with it. While there is still uncertainty, it has become increasingly clear over the last year, with the first spread of the Delta variant and now Omicron, that COVID-19 may never fully go away and may be a virus that persists in one variant form or another for the foreseeable future. And like other viruses, new or different vaccines will be needed and new therapies will be developed to minimize the impact and treat COVID-19 more effectively in our most vulnerable populations.
我們仍留意COVID-19相關的持續不確定性及其伴隨的挑戰。雖然仍存在不確定性,但在過去一年中,隨著Delta變異株的首次擴散以及如今的Omicron,情勢愈發明朗:COVID-19可能永遠不會完全消失,並可能在可預見的未來以某種變異形式持續存在。且如同其他病毒,將需要新的或不同的疫苗,並會開發新的療法,以降低影響並更有效地治療COVID-19,特別是在我們最脆弱的人群中。
The reality of living with COVID is one of the government's businesses and communities all over the world are beginning to acknowledge and move towards. At Align, we will do the same.
與COVID共存的現實,是全球各地政府、企業與社區正開始承認並逐步邁向的方向。在Align,我們也將如此。
In closing, I'm going to share some thoughts that I expressed to our employees recently. What we learn in life, both in business and our personal lives, is that we're not fully in control of our environment and destiny. This is a fact of life that we face every day. But not being in control does not mean that we can't make good choices regardless of the situation or challenges we all face. We must look forward focused on the opportunities. Align has numerous growth drivers in a vastly under-penetrated market.
最後,我想分享一些我最近對員工表達的想法。我們在生活中學到的,不論在商業或個人生活裡,是我們並不能完全掌控環境與命運。這是我們每天都要面對的事實。但無法掌控並不代表我們無法在任何情況下、無論面對何種挑戰,都做出好的選擇。我們必須向前看,專注於機會。Align在一個滲透率仍極低的市場中,擁有眾多成長驅動因素。
And while we continue to see some lasting impact and continued uncertainty due to COVID-19, we remain confident in both the enormous opportunity to lead the evolution of digital orthodontics and comprehensive dentistry. We never forget that digital orthodontics presents the fastest growing and largest market in the world of medical devices. We have the greatest Clear Aligner system, scanners, GP lab software in the world and the broadest and deepest digital dental platform.
儘管我們仍看到COVID-19帶來的一些持續影響與不確定性,我們對於引領數位齒顎矯正與全方位牙科演進的巨大機會仍充滿信心。我們從不忘記,數位齒顎矯正是醫療器材領域中成長最快且規模最大的市場。我們擁有全球最優秀的透明矯正器(Clear Aligner)系統、掃描儀、GP實驗室軟體,以及最廣且最深的數位牙科平台。
We have the most recognized consumer brand in the largest direct sales force in the dental space with over 4,000 salespeople supporting over 212,000 doctors and labs and their staff who have incredible skills and dedication to their patients. We have an amazing team of employees committed to our purpose. It's a unique opportunity unlike anything I've ever seen in my career to both continue to grow Align and be part of the positively changing millions of lives by transforming their smiles.
我們在牙科領域擁有最大直銷團隊中最受認可的消費者品牌,超過4,000名業務人員支援逾212,000位醫師與技工所及其員工;他們對病患展現出卓越的專業能力與投入。我們也擁有一支致力於我們使命的優秀員工團隊。這是一個我職涯中前所未見的獨特機會:一方面持續推動Align成長,另一方面透過改變笑容,正向地改變數百萬人的生活。
Thank you for your time today. We look forward to speaking to you again as the year progresses. Now I'll turn the call over to the operator. Operator?
感謝各位今天撥冗參與。我們期待在今年接下來的時間裡再次與各位交流。現在我把電話交給接線員。接線員?
Operator
Operator
(Operator Instructions) Our first question comes from the line of Nathan Rich with Goldman Sachs.
(接線員指示)我們的第一個問題來自高盛(Goldman Sachs)的Nathan Rich。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Joe, thanks for all the details on the outlook. You called out the 300 basis point headwind from COVID in the quarter with the impact, I think, concentrated in December. So maybe a bit higher as we think about what the headwind was exiting the year. Could you maybe talk about how the impact in January as compared to what you experienced in December? And can you maybe elaborate on what you've seen in recent weeks? I'm just looking for a sense of maybe where January is trending and kind of what you're assuming for the balance of the quarter to get you to the guidance that you gave for 1Q?
Joe,謝謝你提供這麼多對展望的細節。你提到本季受到COVID帶來300個基點的不利影響,而且我認為影響主要集中在12月。因此若我們思考年底退出時的逆風,可能還要更高一些。你能否談談1月的影響相較於12月的情況?以及能否進一步說明你在最近幾週看到的狀況?我主要想了解1月的走勢大概如何,以及你對本季剩餘時間的假設,如何支撐你給出的1Q指引。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Look, we saw what we talked about December, we had a rapid decrease through COVID. But what we've seen as we've gone into January is just progressive improvement. And we feel good about that. We feel it's moving in the right way. And it's in direct correlation. We track it around the country with what's going on with Omicron in certain states and certain regions. And remember, this isn't just United States. We've seen this all over the world. We see it in APAC, and we see it in Europe, too, when we track it.
你看,我們在12月看到的情況正如我們所說,因COVID而快速下滑。但進入1月後,我們看到的是逐步改善。我們對此感覺良好,覺得方向是對的,而且這與疫情發展有直接關聯。我們會依據全國各地Omicron在不同州與不同區域的狀況來追蹤。也請記得,這不只是美國;我們在全球各地都看到了。我們在亞太也看到,在歐洲追蹤時也同樣看到。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Okay. And maybe just building on that at a high level, Joe, do you feel like the slowdown, I guess, is primarily a supply issue, just given the practice closures and lockdowns and staffing issues that you cited versus a demand issue? Because I think in your prepared remarks, you also mentioned some impacts from inflation and less stimulus. So I'd just be curious to kind of get your thoughts there.
了解。Joe,再延伸問一下,從更高層次來看,你覺得這次放緩主要是供給端問題嗎?例如你提到的診所關閉、封控以及人力配置問題;還是其實是需求端問題?因為我記得你在事先準備的發言中也提到通膨與刺激措施減少帶來的一些影響,所以想聽聽你的看法。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
No, we don't see this as a demand issue. I mean we look at the market as we always have. That's why we reasserted our 20%, 30% growth rate for this year. So this is not a demand equation issue. You'd call it a supply, but I'd call it demand from a patient standpoint. We just see it's patients and doctors in the sense of cancellations, availability and all those things that COVID has impacted around. So we remain very confident.
不,我們不認為這是需求問題。我們一如既往地看市場,這也是為什麼我們重申今年20%到30%的成長率。因此這不是需求方程式的問題。你可以稱它為供給,但我會從病患端的需求來看:我們看到的是病患與醫師在取消、可用性等方面受到COVID影響。因此我們仍然非常有信心。
That's why you see us to continue to make investments, the things we announced today. We feel really good about the business. We just have to get through this first quarter and what we talked about, and we'll move on. We feel really good about it.
這也是為什麼你看到我們持續投資,包括我們今天宣布的事項。我們對業務感覺非常好;我們只需要度過第一季以及我們所談到的狀況,接著就會往前走。我們對此非常有信心。
Operator
Operator
And our next question comes from the line of Matt Miksic with Crédit Suisse.
下一個問題來自瑞士信貸(Crédit Suisse)的Matt Miksic。
Matthew Stephan Miksic - Senior Research Analyst
Matthew Stephan Miksic - Senior Research Analyst
Just maybe a follow-up on that, the question on planning assumptions around your Q1 comments and 2022 guidance. Maybe, Joe, if you could just give a sense as to how -- you mentioned improvements in early January. Is this kind of sluggish recovery wrapping up by the end of the quarter? Is Q2 the inflection to help you get to that 20% to 30% growth that you mentioned?
我想就此追問一下,關於你們第一季評論與2022年指引的規劃假設。Joe,你能否說明一下——你提到1月初有所改善。這種偏疲弱的復甦會在本季末結束嗎?第二季是否會成為拐點,幫助你達到你提到的20%到30%成長?
And then just if I could also on a similar topic. Just the idea that somehow there is -- you've -- I think many of the folks on the call have heard this idea that somehow there was outsized growth during the pandemic and we're sort of digesting that somehow now, which I know is sort of one of the ways that folks look at Align and at aligners and so on.
另外我也想問一個相關主題:有一種說法——我想很多與會者都聽過——認為疫情期間出現了超常的成長,而我們現在某種程度上正在消化那段成長;這也是一些人看待Align、以及隱形矯正器等產品時的角度。
If you could maybe just talk about your confidence that once we get through the staffing that the demand that's in front of you, the growth drivers that you're laying in on top of your core markets, that we're not looking to digest some sort of outsized growth during the pandemic here in '22, but we're getting back to a growth market that's still highly under-penetrated? Sorry for the lengthy 2-part question, but I would appreciate it.
你能否談談你的信心:一旦我們度過人力配置問題,面前的需求、以及你在核心市場之上所加上的成長驅動因素,是否意味著我們在2022年並不是在消化疫情期間的某種超常成長,而是回到一個仍然高度未滲透的成長型市場?抱歉這個問題分成兩部分且有點長,但我會很感謝你的回應。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We understand the basis of your question, Matt. I mean that's not a problem in that sense. Look, as I mentioned before, we're really confident in demand equation in the sense of Clear Aligners and Invisalign. What we're experiencing right now is obviously somewhat of a slowdown in our order demand pattern based on what we see through the virus that's going on around the world. As soon as that clears and we see it clearing around the world, and as I mentioned, we see January improving over December, we're very confident in demand models that we've expressed for this business over the last several years.
Matt,我們理解你問題的出發點,這沒有問題。你看,正如我之前提到的,我們對於透明矯正器與Invisalign的需求面非常有信心。我們目前經歷的,顯然是因全球病毒情勢而導致的訂單需求型態某種程度的放緩。一旦情況緩解——而我們也看到全球正在緩解——如我所說,1月相較12月正在改善,我們對於過去幾年所表達的這項業務需求模型仍然非常有信心。
Operator
Operator
And our next question comes from the line of Elizabeth Anderson with Evercore ISI.
下一個問題來自Evercore ISI的Elizabeth Anderson。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
I guess on the first side, I think you obviously talked about some of the increased investments that you're making on marketing and also in sales capacity, et cetera. How do we think about the conversion efforts of those initiatives versus sort of prior, and sort of where do you sort of see that hitting in terms of as we're thinking about the pacing of the year?
我想先問第一部分:你們顯然談到正在增加一些投資,包括行銷以及銷售產能等。相較於過去,我們應該如何看待這些措施的轉換成效?以及在思考全年節奏時,你們預期這些投資會在什麼時點反映出來?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I mean the pacing of the year -- I mean we continue to invest, as we mentioned, John mentioned, I mentioned, too, in marketing. Where we invest? We understand the returns that we get, no matter what the country is or what kind of media we use in order to go after consumers. So we've been very consistent in the sense of that investment. And we move money around based on where we see the most opportunity. John, anything to add?
是的。就全年節奏而言——我們持續投資,如我們提到的,John提到、我也提到,在行銷方面。我們投資在哪裡?我們了解不論是哪個國家、或使用何種媒體去觸及消費者,我們能獲得的回報。因此在投資上我們一直非常一致。我們也會依據看到的最大機會來調整資金配置。John,有沒有要補充的?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And we -- as we mentioned, we added some sales resources in Q4 to get ahead of sales territories and changes and so on. We saw that show up in Q4, but it really gives us the opportunity then to be able to grow as we get into this year. So it's continued investments to drive the biggest return, and that's what we're continuing to do.
另外,如我們所提到的,我們在第四季增加了一些銷售資源,以提前因應銷售區域與變動等。我們在第四季已看到其反映,但這也讓我們在進入今年後有機會成長。因此這是持續投資以帶來最大回報,而這正是我們持續在做的事。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Okay. So it sounds like maybe no change in sort of the pacing that we've been seeing before. Maybe as a follow-up, I know you obviously highlighted that the total growth of the company would be in your 20% to 30% range. Do you also see that the case growth on a year-over-year basis would be above 20% as you look out at this point?
了解。所以聽起來你們在全年節奏上可能沒有改變,仍與之前看到的相近。再追問一下,我知道你們強調公司整體成長會落在20%到30%的區間。以目前的展望來看,你們是否也認為病例數(case)年增率會高於20%?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
We'd expect them to be similar. When we talk about 20% to 30%, we're talking about revenue for the entire company. But they would be similar from an outlook standpoint.
我們預期會相近。當我們談20%到30%時,我們指的是整個公司的營收。但從展望角度來看,它們會是相近的。
Operator
Operator
And our next question comes from the line of Jon Block with Stifel.
下一個問題來自Stifel的Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Maybe just the first one. The op margin compression year-over-year, the 24.7-ish gap that is to the 24%, maybe you could talk to that. John, I was thinking you were just going to say it's a gross margin thing with scanners likely to grow much faster than case. But to Elizabeth's question, it seems like you expect both to be within the guardrails of 20% to 30%. So is it more a function of you guys just sort of, call it, running a little bit harder on the OpEx line to drive that case volume? And why we would see that year-over-year OM compression. Again, I'm just sort of referring gap-to-gap for apples-to-apples?
先問第一個。營業利益率(op margin)年對年下滑,從約24.7%到24%之間的差距,你們能否談談原因?John,我原本以為你會說這是毛利率的問題,因為掃描器的成長可能比病例數快得多。但依照Elizabeth的問題,你們似乎預期兩者都會落在20%到30%的範圍內。所以這是否更多是因為你們在營業費用(OpEx)端投入得更積極,以推動病例量?以及為什麼我們會看到年對年營業利益率壓縮?我指的是以可比口徑來看,從一個差距到另一個差距的比較。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
I think, Jon, it's continued investments like we have with the story to continue to invest that we have and being able to be able to grow into this market. So I think when we look at it overall, we're kind of pegging the GAAP rate to be at 24% for 2022, and we'll evaluate and update as we go forward. But it's continuing to invest. We've got, as you know, our Poland facility going live in 2022. And we have some of those moving parts that will impact our gross margin slightly as a result of that. But -- and that translates to op margin. But those are the initiatives that we have, but nothing out of the ordinary that we've done in the past.
Jon,我認為這是持續投資,就像我們一貫的策略一樣,持續投入以便在這個市場中成長。因此整體來看,我們把2022年的GAAP營業利益率設定在24%,並會在往後推進時持續評估與更新。但核心仍是持續投資。你也知道,我們的波蘭廠將在2022年啟用。我們有一些這類變動因素,會因此對毛利率造成些微影響,而這也會反映到營業利益率。不過這些都是我們既有的計畫,並沒有任何不同於過去的異常之處。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. Heads up, this next one is going to be long, probably 2 parts. But maybe can you just get people comfortable with the fact that if you look at your 2Q, 3Q, 4Q '21 case files and the implied guidance for 1Q, to get to 20% to 30% case volumes for the year, you're going to have to rip sequentially in 2Q, 3Q, 4Q of '22. Maybe if you could talk to that?
好的。先提醒一下,下一題會很長,可能要分成兩部分。不過也許你能先讓大家接受這個事實:如果你回頭看你們在 2021 年第 2 季、第 3 季、第 4 季的病例檔案,以及對 2022 年第 1 季的隱含指引,要達到全年 20% 到 30% 的病例量,你們就必須在 2022 年第 2 季、第 3 季、第 4 季按季大幅拉升。也許你可以談談這點?
And then the other sort of third question, if you would, admittedly is I'm confused on the 3 points. So if 4Q was impacted by 3 points of growth, why don't we capture, I don't know, 2 or 3 points of that in 1Q '22? Where are those cases going if they're not showing up in the next possible quarter?
然後另外一個、算是第三個問題,如果可以的話,坦白說我對這 3 個百分點有點困惑。所以如果第 4 季的成長受到 3 個百分點的影響,為什麼我們在 2022 年第 1 季沒有捕捉到其中、我不知道,2 或 3 個百分點?如果它們沒有在下一個可能的季度出現,那些病例都跑到哪裡去了?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
I think I'll maybe start with the last part of your question, Jon. When you think of what's happened in the world with Omicron and the effects of that, it's affecting parts of the world at different phases. You see it even within the U.S. Northeast maybe gets hit with it first. It starts to open up later. After that, maybe other parts of the country get impacted. So it's not like it just happens and you immediately get it back. It comes down to when people are able to go to work, in this case, at doctors' offices, to be able to provide care and then it comes down to when patients feel comfortable to be able to go back in.
Jon,我想我先從你問題的最後一部分開始。當你想到 Omicron 在全球發生的情況以及其影響時,它在世界各地的不同階段影響不同地區。即使在美國境內你也看得到,東北部可能先受到衝擊,之後才開始重新開放。再之後,可能國內其他地區才受到影響。所以不是說事情一發生,你就立刻把量拿回來。關鍵在於人們何時能回去上班——在這個情境下是到診所——才能提供醫療服務;也取決於病患何時覺得安心、願意再回來就診。
And so it's not an immediate effect in how we look at it. So think of -- and what we've learned from kind of COVID 1.0, the first time we saw this, we know that there's an impact, and then there's a recovery period. And that's our best view of that recovery period.
因此從我們的角度來看,它不是立即性的影響。你可以想想——我們從某種程度上的 COVID 1.0,也就是第一次看到這種情況時學到的是:會先有衝擊,接著會有一段復甦期。而這就是我們對那段復甦期的最佳判斷。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
John, on your other part about you have to writ the rest of the year, we understand that. I mean we've modeled it out. Remember, our comparisons are a little better second half than they were first half when you look at what we did in 2021 in the first half of the year. So look, we wouldn't make that prediction if we didn't think it was feasible based on what we've seen and what we've modeled.
John,關於你提到今年剩下的時間必須加速成長的那部分,我們理解。我們的確已經把它建模出來。記住,當你看 2021 年上半年我們的表現時,我們在下半年的比較基期會比上半年更有利。所以你看,如果我們不認為基於我們看到的情況與模型推演是可行的,我們不會做出那樣的預測。
Operator
Operator
Our next question comes from the line of Jeff Johnson with Robert W. Baird.
我們的下一個問題來自 Robert W. Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Just a couple of questions here from me. I guess one, John, in 2021, you guys were talking about being within your LRP, but at the upper end of that. Do you want to put any qualifiers on kind of the LRP for 2022? It feels like kind of low end, given where 1Q is starting. But one, do you want to put any qualifiers around where within that LRP you'd expect to be?
我這邊有兩個問題。第一個,John,在 2021 年你們談到會落在你們的 LRP 範圍內,但會偏向上緣。對於 2022 年的 LRP,你們想加上任何限定或補充說明嗎?考量第 1 季的起點,看起來比較像是偏低端。但第一,你們是否想就你們預期會落在 LRP 的哪個位置做些說明?
And two, just to go back to the last 2 questions again. I feel like I'm talking to my 10-year-old kid here, so apologies. But I'm going to give you one more chance. Do you feel like case shipments can still grow within that LRP this year, too, not just revenue? Because you've got some of the new products you're selling, plus you've got faster iTero growth in that, but case shipments also can be within that 20% to 30% LRP. I just want to make sure I'm hearing that correctly.
第二個,再回到前面那兩個問題。我覺得我好像在跟我 10 歲的小孩講話一樣,所以先道歉。但我再給你們一次機會。你們是否覺得今年病例出貨量也仍然可以在那個 LRP 範圍內成長,而不只是營收?因為你們有一些新產品在賣,加上 iTero 成長更快,但病例出貨量也可以落在那個 20% 到 30% 的 LRP。我只是想確認我聽得沒錯。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
I can answer both of those, Jeff, in terms of the 20% to 30%. We're not going to call kind of high/low on that. We're reaffirming our 20% to 30%, similar to what we talked about at Investor Day despite some of the things that we've talked about here with Omicron and some of those COVID cases and so on. But when we look at Invisalign case volume, we would expect to be in and above that range. So nothing out of the ordinary from what we expect. We don't see -- our ASPs were very similar to what they were in the prior quarter. Provided that there's not FX or other things that we're not projecting now and if there's no change there, we would expect to be in that range as well.
Jeff,關於 20% 到 30% 這點,我可以回答你這兩個問題。我們不會去定義那個區間的高端或低端。我們重申 20% 到 30% 的目標,和我們在投資人日談到的類似,儘管我們在這裡談到 Omicron 以及一些 COVID 病例等因素。但當我們看 Invisalign 的病例量時,我們預期會落在該區間內,甚至高於該區間。所以沒有任何超出我們預期的異常。我們沒有看到——我們的 ASP 與前一季非常接近。只要沒有我們目前未預測到的匯率(FX)或其他因素、且沒有變化,我們也預期會落在那個範圍內。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Fair enough. And then, Joe, maybe kind of just update us on kind of the competitive landscape. We've seen a couple of DSO contracts get announced here from others in the last few months and maybe some talk over in China about some growing competition or slowing end markets in that. But where do you see your end markets across the globe from a competitive standpoint? Would just love to hear your update there.
了解。那 Joe,也許請你更新一下競爭態勢。我們看到過去幾個月有其他公司宣布了幾個 DSO 合約,另外在中國那邊也有一些關於競爭加劇或終端市場放緩的討論。但從競爭角度來看,你怎麼看你們在全球各地的終端市場?很想聽聽你的最新看法。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jeff, I think from a competitive standpoint, nothing has really changed. As we look out there, you can see the tech we just announced this. We move on in the sense of our capabilities, what we can do. My position has always been that competition isn't really affecting us from a price standpoint. I think you see that and what we're doing. But they do serve to help to broaden the market and increase the market and make -- and increase the awareness.
Jeff,我認為從競爭角度來看,其實沒有太大改變。放眼市場,你可以看到我們剛宣布的技術;我們在能力上持續前進、持續提升我們能做的事情。我的立場一直是:競爭在價格層面並沒有真正影響到我們。我想你從我們的作為也看得出來。但競爭確實有助於擴大市場、增加市場規模,並且——提升市場認知。
So we feel we are -- in this kind of competitive environment, we're doing well, and we lead in this sense. And there's nothing as we go into 2022 that I won't reflect on that's changed competitively than what I've seen over the last 3 years.
所以我們覺得在這樣的競爭環境中,我們做得很好,而且在這個意義上我們是領先者。展望 2022 年,從競爭面來看,沒有任何事情讓我覺得相較於過去 3 年我所看到的情況有什麼改變。
Operator
Operator
And our next question comes from the line of John Kreger with William Blair.
我們的下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
John, 2 quick ones for you. I think you said that the receivable DSOs were up about 7 days year-over-year. Can you just expand on that? Was that -- were you providing some extra inducements to practices or anything to be concerned about there?
John,我有兩個很快的問題。我想你提到應收帳款的 DSO 年增大約 7 天。你能再多說明一下嗎?那是——你們有提供診所一些額外的誘因之類的嗎?這部分有什麼需要擔心的嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Nothing to be concerned. We're in a fortunate cash position as a company to be able to generate a lot of CFOA and free cash flow. And in working with doctors to be able to give them more flexibility, sometimes we'll extend payments. But we've actually seen historically low amount of past dues as we've gone through this time period in 2021. So we feel very comfortable with that. It's just working with doctors to kind of meet their cash flow needs, but nothing out of the ordinary.
沒有什麼需要擔心的。我們公司現金部位很充裕,能夠產生大量的 CFOA 和自由現金流。在與醫師合作、提供他們更大彈性時,我們有時會延長付款期限。但在 2021 年這段期間,我們其實看到逾期款項處於歷史低位。所以我們對此非常放心。這只是與醫師合作、在某種程度上滿足他們的現金流需求,沒有任何不尋常之處。
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
Okay. Great. And then one other one to clarify. I think you said that you expect the EBIT margin to be under 20% in the first quarter. Was that GAAP or non-GAAP?
好的。那再釐清另一點。我想你說你預期第一季 EBIT 利潤率會低於 20%。那是 GAAP 還是 non-GAAP?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
That's GAAP.
那是 GAAP。
Operator
Operator
Our next question comes from the line of Jason Bednar with Piper Sandler.
我們的下一個問題來自 Piper Sandler 的 Jason Bednar。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Joe, just real quick, and I asked whether you can confirm, you said January improved over December. I thought I heard you say that earlier in the call. Or is it just that the January trend line showed improvement as the month unfolded? Sorry for just clarifying that something nuance like that here.
Joe,很快確認一下,我之前問你能否確認:你說 1 月比 12 月有改善。我以為我在電話會議前面聽到你這麼說。還是說只是 1 月的趨勢線在整個月的進程中顯示出改善?抱歉,我只是想釐清這種細微差異。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. I think to clarify, Jason, the month end showed improvement versus December. It was -- it's how COVID spreads across, whether it's one country or parts of countries and so on and how it affects the staff and how it affects the patients in. But as we exited, we're in a better trend line than we started the month with.
是的。Jason,為了釐清,月底的表現相較於 12 月是有改善的。這取決於 COVID 如何擴散——不論是一個國家或是一個國家的部分地區——以及它如何影響員工、如何影響到進來就診的病患。但當我們離開 1 月時,我們的趨勢線比月初時更好。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Okay. Understood. And then maybe as a follow-up to an earlier question, really for Joe or John. I know you often talk about the internal investments you keep making in the business. You talked about running a similar growth algorithm here in '22 as you have in the past. But we also have 2 different case examples here of the market. With pre-COVID, a lot of those resources were helping funding faster growth in your team business. And then the last 18 months during the pandemic, adult demand has really taken off and growing faster than teens.
好的,了解。那也許作為對先前問題的追問,主要想問 Joe 或 John。我知道你們常談到持續在業務上做內部投資。你們提到在 2022 年會延續過去類似的成長演算法。但我們也看到市場上有兩個不同的案例。COVID 之前,很多資源是在支持你們青少年業務更快成長。然後在疫情期間的過去 18 個月,成人需求確實大幅起飛,成長速度也快於青少年。
So I guess my question here is, as you went through your year-end planning and you're obviously resourcing this business in another significant way here in '22, how do you approach it for this year? Is it from a sales force add, marketing plan and whatnot? Is it -- are you -- really with respect to how you're thinking about the adult and teen mix that you're expecting for this year?
所以我想我這裡的問題是,當你們進行年終規劃、而且顯然在 2022 年以另一種重大的方式為這項業務配置資源時,你們今年會如何著手?是從增加銷售團隊、行銷計畫等等來看嗎?也就是說——就你們對今年預期的成人與青少年組合而言,你們是如何思考的?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I mean we're -- it's Joe, Jason. I mean there's no big change in the sense of what we think the critical drivers are that we have to invest in to drive growth. Where we invest and how we invest is really important. When you look at technology, when you look at consumer pieces, however parts of those demand inflations you want to go to. But remember, there are certain ratios that we always hold to in this business is that what we invest in. And we hold ourselves accountable for those ratios and that performance from a profitability standpoint. But I can't overstate the importance of having a strong sales force.
我的意思是——我是 Joe,Jason。我的意思是,在我們認為必須投資以推動成長的關鍵驅動因素方面,沒有什麼重大改變。我們投資在哪裡、以及如何投資,才是真正重要的。當你看技術、看消費者端的部分,無論你想把那些需求通膨的部分導向哪裡。但請記住,在這個業務中我們一直遵守某些比率,也就是我們投入的資金。我們也要求自己對這些比率以及從獲利角度的表現負責。但我再怎麼強調擁有強大的銷售團隊的重要性都不為過。
We talked about additional salespeople we're putting in place. Our consumer brand means a lot in the sense of our growth. And that's becoming more and more sophisticated in the sense of where we spend those dollars and how we spend those dollars. But leading in technology, you have to have technology in this business. And that's why we're excited to really announce what we did today. We've been working on these programs for 3 years or more. And these are game-breakers in the sense of how you interface with a doctor and how a doctor interfaces with patients.
我們談到我們正在增設的額外銷售人員。我們的消費者品牌在成長方面意義重大。而且在我們把錢花在哪裡、以及如何花這些錢方面,正變得越來越精細、越來越成熟。但在技術上領先——你在這個業務中必須具備技術。這也是為什麼我們很興奮能真正宣布我們今天所做的事情。我們已經在這些專案上投入了 3 年或更久。就你如何與醫師互動、以及醫師如何與病患互動而言,這些都是顛覆性的突破。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And I would just add to that, Jason. We're investing with that return on investment in mind. That's how we look at our long-term growth model. And when we make investments, we have that in mind. In some countries, you're going deeper, you're adding more salespeople to get closer to doctors and really trying to drive that utilization. In other areas where you don't have a direct sales force, you're just adding and just trying to get the breadth in there.
Jason,我也補充一下。我們投資時會把投資報酬率放在心上。這就是我們看待長期成長模型的方式。當我們做投資時,我們心裡就有這個考量。在某些國家,你會更深入——你會增加更多銷售人員,以更貼近醫師並真正推動使用量。在其他你沒有直營銷售團隊的地區,你只是增加人手,並試著在那裡擴大覆蓋面。
And then we've been talking about a lot of the marketing activities and other things that we do to drive that awareness in some of those markets and coupled with the research and development investments. Some of it operations, again, to get closer to our customers like in Poland. So it's a multitude of investments, but we look at it with how do we generate the best return, and there's multiple different ways that we do it across these functions.
然後我們也談了很多行銷活動以及我們在某些市場為了提升認知所做的其他事情,並結合研發投資。其中一部分是營運面——同樣是為了更貼近我們的客戶,例如在波蘭。所以這是多方面的投資,但我們看待它的方式是:如何產生最佳回報,而我們在各個職能上有多種不同的做法。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thanks, Jason. Operator, we'll take one more call, please?
謝謝你,Jason。接線員,請再接一通電話?
Operator
Operator
Sure. The last question we have is from the line of Brandon Couillard with Jefferies.
好的。我們最後一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
John, you've talked about freight costs for a few quarters now. Any chance you're planning a list price increase this year to help offset some of that? It's been a few years since you've taken less pricing?
John,你們已經談了幾季的運費成本。今年你們有可能計畫調高牌價(list price)來抵消其中一部分嗎?你們已經有幾年沒有調價了?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, it's a good question. We are seeing freight -- it looks like many companies have. We have a lot of plans in place to drive productivity. The operating team is very aware of our cost inputs and where we can drive productivity, getting closer to our customers, like we talk in Poland. Once we get there, that will be a freight savings. And once we're operational there, and that will help. But we haven't really finalized any plans on a price increase.
是的,這是個好問題。我們確實看到運費——看起來很多公司也是如此。我們有很多計畫在推動生產力提升。營運團隊非常清楚我們的成本投入,以及我們可以在哪些地方提升生產力,例如我們在波蘭談到的、更貼近客戶。一旦我們到位,那將帶來運費節省。而一旦我們在那裡開始營運,這也會有所幫助。但我們尚未真正敲定任何漲價計畫。
We'll evaluate as we go through. And the first people that we talk to would be our customers. But you're right, we understand the price is important, but we're also very sensitive to our customers and what they've had to go through as we've been on this COVID journey. So nothing in the works now.
我們會在推進過程中評估。而我們首先會溝通的對象會是我們的客戶。但你說得對,我們理解價格很重要,但我們也非常體恤客戶,以及在這段 COVID 歷程中他們所必須經歷的一切。所以目前沒有在進行中的計畫。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Okay. And then Joe, on iTero, I appreciate the detail as far as more than 50% of placements being new buyers. I would actually expect that to be normally the case. So what's the relevancy of that metric? Is that up a lot compared to historical levels? And what percent of those placements are being used for Invisalign case submissions?
好的。然後 Joe,關於 iTero,我很感謝你提供的細節——超過 50% 的裝機(placements)來自新買家。我其實會預期通常就是這樣。所以這個指標的相關性是什麼?相較於歷史水準是否大幅上升?另外,這些裝機中有多少百分比是用於 Invisalign 病例提交(case submissions)?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Over the years, Brandon, we've obviously seen that correlation, and we've communicated it to you in the sense if you sell more iTero scanners, you sell more Invisalign. And that's obviously the front end of our digital system, and it works for us really well. We just [set aside] the 50% because, one, you saw we had a very strong fourth quarter for iTero. And we always have strong fourth quarters. So this was exceptional in that sense.
Brandon,多年來我們顯然看到那種相關性,而且我們也向你們傳達過:你賣出更多 iTero 掃描儀,就會賣出更多 Invisalign。那顯然是我們數位系統的前端,而且對我們非常有效。我們特別提出 50% 的原因是:第一,你看到我們 iTero 第四季非常強勁。而我們第四季一向都很強。所以在這個意義上,這次是特別突出的。
And it was a good signal from the practices that we're dealing with that this had to do with the day-to-day flow that you see from an Invisalign patient standpoint. It had nothing to do with their enthusiasm in the sense of embracing the digital environment that we're talking about. So to see the number of sales that we had really in the last couple of weeks of the quarter, it was just a good signal for us. And we wanted to share that with you is that this market is embracing digital even when it's under pressure. And we're performing really well in that area.
而且,這也從我們所接觸的診所端釋放出一個良好訊號:這與你從 Invisalign 病患角度看到的日常流量有關;而不是因為他們在擁抱我們所談的數位環境方面的熱情。因為在本季最後幾週我們的銷售數量確實很高,這對我們來說是一個很好的訊號。我們也想與你分享:即使在壓力之下,這個市場仍在擁抱數位化,而我們在那個領域的表現也非常好。
As far as 50%, whatever and how -- I don't know exactly what the historical percentages are in that way. But we're -- obviously, what we're excited about is once those scanners are in place, it gives us a good foundation to sell Invisalign.
至於 50% 之類的數字,以及——我不確定歷史上的百分比究竟是多少。但我們——顯然我們感到興奮的是,一旦那些掃描儀裝機到位,就為我們銷售 Invisalign 提供了良好的基礎。
Operator
Operator
And we have reached the end of our question and session. I now turn the call back over to Shirley Stacy for closing remarks.
我們的問答環節到此結束。現在我把電話交回給 Shirley Stacy 作結語。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you. Thanks, everyone, for joining us today. We look forward to speaking to you at upcoming financial conferences and industry meetings. If you have any questions or follow-up, please contact our Investor Relations team. Have a great day.
謝謝。感謝各位今天加入我們。我們期待在接下來的財務會議與產業會議上與各位交流。如果你有任何問題或需要後續跟進,請聯絡我們的投資人關係團隊。祝各位有美好的一天。
Operator
Operator
This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.
今天的電話會議到此結束,現在您可以掛斷電話線。感謝您的參與。